CD3 Antibody Affinity Tuning for Cytokine Storm Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CD3-targeting antibodies can cause excessive activation of T cells and cytokine release, leading to cytokine storm syndrome with severe side effects, necessitating low dosages and a narrow therapeutic window.
Innovation Solution
Development of novel CD3 antibodies and multispecific antibodies targeting CD3 and additional antigens, such as MSLN, which moderate T cell activation and reduce cytokine release, thereby enhancing safety and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Power
If high affinity CD3 antibodies are used to activate T cells, then T cell activation is enhanced, but cytokine storm syndrome occurs with severe side effects
Solution Approach 1:
The patent modifies the affinity parameters of CD3 antibodies by introducing specific amino acid mutations in the complementarity determining regions (CDRs). The mutated CDRs reduce binding affinity to CD3 compared to wild-type antibodies, which in turn moderates T cell activation strength and reduces cytokine release, thereby preventing cytokine storm syndrome while maintaining therapeutic efficacy.
2Object-affected harmful factors
If low dosage is used to reduce cytokine storm risk, then safety is improved, but therapeutic window becomes narrow and patient benefit is reduced
Solution Approach 1:
The patent changes the pharmacokinetic parameters of CD3 antibodies through affinity maturation. By optimizing the balance between binding affinity and cytokine release, the mutated antibodies achieve a shifted dose-response curve that allows for higher dosages without triggering cytokine storm, thereby expanding the therapeutic window while maintaining safety.
3Productivity
If multispecific antibodies targeting CD3 and tumor antigens are developed, then tumor cell killing is enhanced, but complexity of antibody structure increases
Solution Approach 1:
The patent segments the antibody molecule into distinct functional domains: a CD3-targeting arm for T cell activation and a tumor antigen-targeting arm for tumor cell recognition. This segmentation allows each domain to be optimized independently for its specific function while being connected through a linker region, achieving dual functionality without excessive overall complexity.
Solution Approach 2:
The multispecific antibody is designed to perform multiple functions simultaneously: activating T cells through CD3 binding and directly targeting tumor cells through tumor antigen binding. This multi-functionality is achieved by incorporating both CD3 and tumor antigen specificities within a single antibody molecule, thereby enhancing tumor cell killing efficiency while maintaining manageable structural complexity through modular design.
Data Source
AI summary
An antibody targeting CD3 or an antigen-binding fragment thereof, which has a moderate ability to activate T cells and can effectively reduce cell factor release. A multispecific antibody targeting CD3 and other antigens, such as tumor-associated antigens and/or immune checkpoint molecules, which can significantly reduce cytokine release while ensuring efficient and specific killing of target cells, and has a significantly improved safety. The present invention also relates to uses of the antibody targeting CD3 or the antigen-binding fragment thereof, and the multispecific antibody or a composition comprising same in disease treatment.